Description

1 α-(4-(n-Succinimidoxycarbonyl)Butyryl)Mitomycin C is a chemically modified derivative of the potent antitumor antibiotic Mitomycin C, designed for targeted drug delivery and bioconjugation applications. This compound is engineered to act as a key intermediate in the synthesis of antibody-drug conjugates (ADCs) and other targeted therapeutics, enabling the precise delivery of cytotoxic payloads to cancer cells. It is primarily utilized by pharmaceutical researchers and biotech companies engaged in the development of novel oncology treatments and advanced bioconjugation strategies.

Application

• Antibody-Drug Conjugate (ADC) Payload Linker: A critical intermediate for attaching the potent Mitomycin C warhead to monoclonal antibodies via a cleavable or non-cleavable linker system.
• Targeted Cancer Therapy Development: Used in research and development of novel chemotherapeutic agents designed for site-specific action, minimizing systemic toxicity.
• Bioconjugation Chemistry: Serves as an activated ester reagent for coupling to amines on proteins, peptides, or other targeting molecules under mild aqueous conditions.
• Prodrug Synthesis: Employed in the creation of prodrugs that release the active Mitomycin C moiety upon specific enzymatic or environmental triggers within tumor tissue.
• Pharmaceutical Intermediate: A high-value building block in the multi-step synthesis of complex investigational new drugs (INDs).
• Research Tool in Oncology: Utilized in academic and industrial laboratories to study drug delivery mechanisms and the efficacy of targeted cytotoxins.

Basic Information

Product Name	1 α-(4-(n-Succinimidoxycarbonyl)Butyryl)Mitomycin C
CAS No.	90906-09-5
Molecular Formula	C26H28N4O10
Molecular Weight	556.52 g/mol
Synonyms	Mitomycin C N-succinimidyl ester derivative; 1α-(4-(N-Succinimidoxycarbonyl)butyryl)mitomycin C; Mitomycin C activated ester; NSC 710027; 7-N-[4-(Succinimidoxycarbonyl)butyryl]mitomycin C; 1α-(4-((2,5-Dioxopyrrolidin-1-yl)oxy)-4-oxobutanoyl)mitomycin C; Mitomycin C-SI; ADC linker-mitomycin C conjugate
EINECS	Contact for details

Quality Control

This high-purity pharmaceutical intermediate is manufactured under controlled GMP-like conditions to ensure batch-to-batch consistency and reliability for critical research applications. Every lot is subjected to comprehensive analytical characterization, including HPLC purity analysis, NMR, and mass spectrometry for structural confirmation. A detailed Certificate of Analysis (COA) is provided with each shipment, documenting identity, purity, and impurity profiles to support regulatory filings and research integrity.

Storage

Preserve in a tightly closed container, protected from light. Store at -20°C or below in a dedicated freezer. This compound is hygroscopic (moisture-sensitive) and light-sensitive; containers should be allowed to equilibrate to room temperature before opening to minimize condensation. For long-term storage, consider under an inert atmosphere.

Specification

Item	Specification
Appearance	Light yellow to purple solid
Identification (HPLC)	Retention time corresponds to reference standard
Identification (NMR)	Spectrum consistent with structure
Purity (HPLC)	≥ 95.0%
Water Content (KF)	≤ 2.0%
Single Unknown Impurity (HPLC)	≤ 1.0%
Total Impurities (HPLC)	≤ 5.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.